Conective tissue disease
Conditions
Interventions
1.We measure the blood concentration (dosage 12 hours later trough value) of the tacrolimus hydrate in early middle, and latter pregnancy 2.We gather umbilical cord blood (umbilical cord artery) at t
s milk. I measure the blood concentration (dosage 12 hours later) of the tacrolimus hydrate by periodical drawing blood.
Sponsors
Osaka medical College
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Outpatient of our hospital with conective tissue diseases such as mixed connective tissue disease, a scleroderma, skin myosis, polymyositis, Sjogren's syndrome, mixed connective tissue disease, the rheumatoid arthritis 2. During the pregnancy or for after giving birth less than two years or the patient that the pregnancy is admitted in 3.The patient who uses a tacrolimus hydrate 4.Children of the above1-3 patient
Exclusion criteria
Exclusion criteria: non
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| we measure the blood concentration (dosage 12 hours later trough value) of the tacrolimus hydrate at the the time of early, middle,latter pregnancy. We gather umbilical cord blood (umbilical cord artery) at the time of placenta delivery and measure blood concentration of tacrolimus. After consent was obtained, we gather the blood of some children (from three months to six months after birth) and measure blood concentration (dosage 12 hours later) of tacrolimus. For a patient nursing, we measure the density of tacrolimus in mother's milk (the dosage ago dosage three hours later dosage 12 hours later). we measure the blood concentration (dosage 12 hours later) of the tacrolimus hydrate by periodical drawing blood. | — |
Countries
Japan
Contacts
Public ContactShuzo Yoshida
Osaka Medical College Rheumatology, Department of Internal Medicine 1
Outcome results
None listed